Compare Celsius Holdings, Inc. (CELH) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs GSK plc — how do they compare? Celsius Holdings, Inc. trades at $30.15 (market cap $7.71B), while GSK plc trades at $51.18 (market cap $101.55B). The key difference: GSK plc is far larger — about 13.2× Celsius Holdings, Inc.'s market cap, and GSK plc pays a 3.5% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| CELH | GSK | |
|---|---|---|
Market Cap | $7.71B | $101.55B |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $61.18 |
52-Week Low | $27.75 | $36.20 |
Enterprise Value | $9.58B | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Celsius Holdings (CELH) trades at $29.83, down 2.52% on the day, amid bearish technical signals despite strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $2.52B, though net margins have compressed to 4.29%. Recent quarters consistently beat EPS estimates, but cash flow turned negative due to heavy investing activity. Legal investigations and competitive pressures weigh on sentiment, while a $52.30 consensus price target implies significant upside.
Outlook remains bifurcated: high growth potential and international expansion contrast with margin pressure and litigation risks. Investors face a volatile growth story where execution on profitability and market share gains will dictate performance. The stock's high P/E of 71.16 demands sustained earnings acceleration to justify valuation.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
